<DOC>
	<DOCNO>NCT01844336</DOCNO>
	<brief_summary>The purpose study evaluate performance PBASE system , term efficacy treatment patient idiopathic rhinitis .</brief_summary>
	<brief_title>PBASE System Idiopathic Rhinitis Clinical Investigation</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Patients persistent ( &gt; 12w ) symptom idiopathic rhinitis dominate nasal congestion ( Â± secretion ) average least 1 h per day least 5 day period 14 day Having nasal congestion major symptom , nasal congestion score least 2 ( scale 03 ) Male female 18 65 year Judged Investigator suitable participation study without safety concern base medical history physical examination . Willing able provide write informed consent prior participation clinical investigation Willing able comply study related procedure Patients Allergic rhinitis , demonstrate either positive skin prick test , phadiatop RAST Ongoing respiratory tract infection include nasal cavity inclusion ( treatment visit 1 ) Systemic steroid treatment le 4 week inclusion study Patients history nasal surgery like : septoplasty , cosmetic surgery , conchal surgery nasal surgery except closed reposition nasal fracture History frequent nose bleed condition increase risk excessive bleeding Pronounced anterior septal deviation significant nasal pathology endoscopic examination Current malignancy kind Known allergy polyvinylchloride medicinal liquid paraffin Any disease , condition ( medical surgical ) , opinion investigator , might compromise study result , would place subject increase risk . Any implant electrical and/or neurostimulator device , include limited cardiac pacemaker , defibrillator , vagal neurostimulator , deep brain stimulation , spinal stimulator , bone growth stimulator , cochlear implant implant head , neck region . Previous treat radiation face , head neck region Female patient pregnant nursing , become pregnant time inclusion study end 8 week followup visit Female patient : unwilling use adequate contraceptive signing inform consent end 8 week followup visit Received study drug clinical trial investigational drug within previous 30 day , 5 halflives , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>